학술논문
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Document Type
Article
Author
Klein, C.; Waldhauer, I.; Nicolini, V.G.; Freimoser-Grundschober, A.; Dunn, C.; Lang, S.; Roemmele, M.; Hofer, T.; van Puijenbroek, E.; Wittig, D.; Moser, S.; Ast, O.; Brünker, P.; Hinton, H.; Saro, J.; Evers, S.; Gerdes, C.; Bacac, M.; Moessner, E.; Umaña, P.; Nayak, T.; Benz, J.; Stihle, M.; Neumann, S.; de Vera Mudry, M.C.; Crameri, F.; Vugts, D.J.; Bolijn, M.; van Dongen, G.; Gorr, I.H.
Source
In: OncoImmunology . (OncoImmunology, 4 March 2017, 6(3))
Subject
Language
English
ISSN
2162402X
21624011
21624011